Literature DB >> 1345871

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.

C P Braegger1, S Nicholls, S H Murch, S Stephens, T T MacDonald.   

Abstract

Measurement of disease activity in patients with inflammatory bowel disease is difficult. The best available methods are complex and time consuming, but it may be possible to use tumour necrosis factor alpha (TNF alpha) concentration in stool as a marker of disease activity. We measured TNF alpha concentrations in stool samples from normal children, infants with diarrhoea, and children with inflammatory bowel disease in active and inactive phases of the disease. In 10 normal children and 14 children with diarrhoea, median stool TNF alpha concentrations were 58 and 45 pg/g stool, respectively. Compared with diarrhoeal controls, stool TNF alpha concentrations were significantly increased in children with active Crohn's disease (n = 13, median 994 pg/g, p less than 0.0002) and active ulcerative colitis (n = 4, range 276-5982 pg/g, p less than 0.003). In patients with inactive disease, either as a result of surgery or treatment with steroids, the concentration of stool TNF alpha fell to those of controls. Measurement of stool TNF alpha concentrations may provide a simple way to monitor disease activity in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345871     DOI: 10.1016/0140-6736(92)90999-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  166 in total

1.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Ulcerative colitis associated with aplastic anemia.

Authors:  Hiroshi Kishikawa; Jiro Nishida; Masaru Nakano; Erika Hirano; Tetsuo Morishita; Hiromasa Ishii
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 3.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 4.  Regulation of intestinal epithelial permeability by tight junctions.

Authors:  Takuya Suzuki
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

5.  Association of inflammatory cytokine gene polymorphisms with inflammatory bowel disease in a Moroccan cohort.

Authors:  N Senhaji; A Serrano; W Badre; N Serbati; M Karkouri; Y Zaid; S Nadifi; J Martin
Journal:  Genes Immun       Date:  2015-12-03       Impact factor: 2.676

Review 6.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

7.  Distinctive pattern of cytokine production and adhesion molecule expression in peripheral blood memory CD4+ T cells from patients with active Crohn's disease.

Authors:  Jaime García de Tena; Luis Manzano; Juan Carlos Leal; Esther San Antonio; Verónica Sualdea; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

8.  Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis.

Authors:  Astrid Konrad; Michael Mähler; Stephan Arni; Beatrice Flogerzi; Sonja Klingelhöfer; Frank Seibold
Journal:  Int J Colorectal Dis       Date:  2004-08-25       Impact factor: 2.571

9.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

Review 10.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.